Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome-Reference-Cited by-同舟云学术

Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome

Published:2023-10-01 Issue:3 Volume:20 Page:1804-1809
ISSN:2667-7849
Container-title:Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
language:
Short-container-title:

Author:

EROL KOÇ Esin Merve¹^ORCID,YAMAN Selen¹^ORCID,CEYHAN Meryem¹^ORCID,NESELİOGLU Salim²^ORCID,EREL Özcan²^ORCID,DOĞANAY Melike³^ORCID

Affiliation:

1. Ankara Şehir Hastanesi

2. ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ

3. SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, GÜLHANE TIP FAKÜLTESİ, GÜLHANE TIP PR. (ANKARA)

Abstract

Aim: The myeloperoxidase/paraoxonase1(MPO/PON1) ratio is known to reflect the dysfunctional HDL(d-HDL) which is a measure of oxidative stress. This study aimed to evaluate the MPO/PON1 ratio in polycystic ovary syndrome(PCOS). Materials and Method: This prospective study included a total of 123 patients. The study group including the women with the diagnosis of PCOS (n=63) was compared to the control group including the healthy women (n=60). Sociodemographic characteristics, and clinical features of the groups were recorded. Serum HDL level, MPO, and PON1 activities were evaluated. Results: The PCOS patients were observed to have increased MPO and decreased PON1 activities (p

Publisher

Ministry of Health, Ankara City Hospital

Subject

General Medicine

Reference5 articles.

1. 1. Escobar-Morreale HF. Polycystic ovary syndrome: de- finition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.

2. 2. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analy- sis. Hum Reprod Update. 2011;17(4):495-500.

3. 3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993-1007.

4. 4. Perovic Blagojevic IM, Vekic JZ, Macut DP, Ignjato- vic SD, Miljkovic-Trailovic MM, Zeljkovic AR, et al. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2022;128(4):604-12.

5. 5. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fo- narow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46(10):1792-8.